Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mFOLFOX7 with alternating BIBF 1120 and BIBW 2992 versus mFOLFOX7 alone in first-line metastatic colorectal cancer
2006-004528-35Phase 2Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in metastatic colorectal adenocarcinoma (mCRC) and colorectal cancer (CRC) comparing mFOLFOX7 plus alternating BIBF 1120 and BIBW 2992 (BB) with mFOLFOX7 alone (2 arms). Primary endpoints: Objective response and Progression-free survival. Started Nov 2006; status: terminated.
02
Drugs
nintedanibafatinibmFOLFOX
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)colorectal cancer (CRC)
Beyond the preview
Go deeper on 2006-004528-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004528-35.